Joel Beatty Recent News
Citi Cuts Novavax's Price Target From $12 To $1.50 Following Failed Trial
Citigroup Downgrades Raptor Pharma; Concerned With Declining Investor Sentiment Around Revenue
Esperion Price Target Cut At Citi On U.S. Approval Likelihood
These Analysts Like Syndax's Breast Cancer Drug
Citi Downgrades PTC Therapeutics Following Major Setback
Citi Sees Limited Sales For Blood-Clot Drug At The Medicines Company